| Guidelines for the use and interpretation of assays for monitoring autophagy DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... Autophagy, 1-382, 2021 | 13147* | 2021 |
| Integrative molecular characterization of malignant pleural mesothelioma J Hmeljak, F Sanchez-Vega, KA Hoadley, J Shih, C Stewart, D Heiman, ... Cancer discovery 8 (12), 1548-1565, 2018 | 481 | 2018 |
| MED12 mutations in leiomyosarcoma and extrauterine leiomyoma G Ravegnini, A Marino-Enriquez, J Slater, G Eilers, Y Wang, M Zhu, ... Modern pathology 26 (5), 743-749, 2013 | 129 | 2013 |
| Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy S Angelini, S Soverini, G Ravegnini, M Barnett, E Turrini, M Thornquist, ... haematologica 98 (2), 193, 2013 | 121 | 2013 |
| Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy S Angelini, MA Pantaleo, G Ravegnini, C Zenesini, G Cavrini, M Nannini, ... Pharmacological research 68 (1), 1-6, 2013 | 80 | 2013 |
| Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST MA Pantaleo, M Urbini, V Indio, G Ravegnini, M Nannini, M De Luca, ... Molecular Cancer Research 15 (5), 553-562, 2017 | 67 | 2017 |
| Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis G Ravegnini, G Sammarini, M Nannini, MA Pantaleo, G Biasco, P Hrelia, ... Autophagy 13 (3), 452-463, 2017 | 64 | 2017 |
| KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation C Serrano, Y Wang, A Mariño-Enríquez, JC Lee, G Ravegnini, JA Morgan, ... Journal of Clinical Oncology 33 (22), e93, 2015 | 61 | 2015 |
| Prognostic role of miR-221 and miR-222 expression in cancer patients: a systematic review and meta-analysis G Ravegnini, S Cargnin, G Sammarini, F Zanotti, JL Bermejo, P Hrelia, ... Cancers 11 (7), 970, 2019 | 55 | 2019 |
| Key genetic and epigenetic mechanisms in chemical carcinogenesis G Ravegnini, G Sammarini, P Hrelia, S Angelini Toxicological Sciences 148 (1), 2-13, 2015 | 47 | 2015 |
| Environmental exposure to benzene, micronucleus formation and polymorphisms in DNA-repair genes: a pilot study S Angelini, F Maffei, JL Bermejo, G Ravegnini, D L’Insalata, ... Mutation Research/Genetic Toxicology and Environmental Mutagenesis 743 (1-2 …, 2012 | 47 | 2012 |
| Personalized medicine in gastrointestinal stromal tumor (GIST): clinical implications of the somatic and germline DNA analysis G Ravegnini, M Nannini, G Sammarini, A Astolfi, G Biasco, MA Pantaleo, ... International journal of molecular sciences 16 (7), 15592-15608, 2015 | 44 | 2015 |
| TRPM2 in the brain: role in health and disease G Sita, P Hrelia, A Graziosi, G Ravegnini, F Morroni Cells 7 (7), 82, 2018 | 39 | 2018 |
| ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular … A De Leo, D de Biase, J Lenzi, G Barbero, D Turchetti, M Grillini, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 36* | 2021 |
| ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular … A De Leo, D de Biase, J Lenzi, G Barbero, D Turchetti, M Grillini, ... Cancers 13 (5), 950, 2021 | 36 | 2021 |
| Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy S Angelini, G Ravegnini, JA Fletcher, F Maffei, P Hrelia Pharmacogenomics 14 (8), 941-956, 2013 | 32 | 2013 |
| Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors MA Pantaleo, G Ravegnini, A Astolfi, V Simeon, M Nannini, M Saponara, ... Epigenomics 8 (10), 1347-1366, 2016 | 30 | 2016 |
| Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia G Ravegnini, G Sammarini, S Angelini, P Hrelia Expert opinion on drug metabolism & toxicology 12 (7), 733-742, 2016 | 29 | 2016 |
| SDHC methylation in gastrointestinal stromal tumors (GIST): a case report M Urbini, A Astolfi, V Indio, MC Heinrich, CL Corless, M Nannini, ... BMC medical genetics 16 (1), 1-4, 2015 | 29 | 2015 |
| miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers M Nannini, G Ravegnini, S Angelini, A Astolfi, G Biasco, MA Pantaleo Epigenomics 7 (6), 1033-1049, 2015 | 27 | 2015 |
